GETAID: Four Decades of Advancements in Inflammatory Bowel Disease Research

Overview

The Groupe d’Etude sur les Affections Inflammatoires Digestives (GETAID) has significantly advanced inflammatory bowel disease (IBD) research over 40 years through innovative clinical trials and collaborative multicenter studies. Their work, including the development of the Crohn’s Disease Endoscopic Index of Severity (CDEIS), has enhanced understanding and treatment of Crohn’s disease and ulcerative colitis.

Background

Founded in 1983 by Professor Robert Modigliani and colleagues, GETAID emerged when IBD clinical evidence was limited and treatment options were scarce. The group aimed to address practical clinical questions through rigorous randomized controlled trials and prospective cohorts across French-speaking countries. Early on, GETAID pioneered objective quantification of disease severity, notably developing the CDEIS to standardize endoscopic assessment in Crohn’s disease. Their collaborative approach has resulted in over 120 peer-reviewed publications, shaping modern IBD management.

Data Highlights

Key Findings

• GETAID was founded to answer clinically relevant questions in IBD through collaborative academic research.
• The group conducted a landmark trial evaluating levamisole in Crohn’s disease before its formal establishment.
• GETAID developed the Crohn’s Disease Endoscopic Index of Severity (CDEIS), enabling reproducible quantification of endoscopic disease severity.
• A pivotal trial showed that extending steroid treatment based on endoscopic severity did not improve mid-term remission in Crohn’s disease.
• GETAID’s approach combined clinical, biological, and endoscopic data to better understand disease evolution under treatment.
• The group’s sustained collaboration and rigorous methodology have led to significant contributions in IBD clinical research over four decades.

Clinical Implications

GETAID’s work underscores the importance of objective disease severity assessment, such as with the CDEIS, in guiding treatment decisions in Crohn’s disease. Their findings caution against prolonging steroid therapy solely based on endoscopic findings without clinical remission, highlighting the need for balanced clinical judgment. The collaborative model exemplified by GETAID can serve as a framework for future multicenter IBD research.

Conclusion

Over 40 years, GETAID has profoundly influenced IBD clinical research by addressing practical questions with innovative trials and standardized assessment tools. Their legacy continues to inform evidence-based management and collaborative research strategies in inflammatory bowel diseases.

References

1. Modigliani et al. 1983 -- Founding of GETAID and early clinical trials
2. Mary et al. 1989 -- Development of the Crohn’s Disease Endoscopic Index of Severity (CDEIS)